Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
评价FS-1502单药静脉滴注在HER2突变或过表达的不可手术切除的局部晚期或转移性非小细胞肺癌患者中的疗效
CTR20220113Phase 2Terminated
- Sponsor
- Fosun Pharma
- Start
- Jan 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of caxmotabart entudotin in non-small cell lung cancer (NSCLC), sponsored by Fosun Pharma. Started Jan 2022; status: terminated.
02
Drugs
caxmotabart entudotin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20220113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220113.